Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rifamycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 5/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | SLCO1A2 | P46721 | 2/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | ABCC4 | O15439 | 4/20 | 0.70 |
| ▸ | ABCC2 | Q92887 | 4/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.70 |
| ▸ | ABCC3 | O15438 | 3/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.70 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.70 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rifamycin SCHEMBL22389512 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL31715824 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL29355202 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL2320 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL151824 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL23370269 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL29649054 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL22553368 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL22389517 | 0.99 | ABCB11 (0.99) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL29816867 | 0.99 | ABCB11 (0.99) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1937 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102392-A1 | PROPHYLACTIC OR THERAPEUTIC DRUG FOR NEURODEGENERATIVE DISEASES | MEDILABO RFP INC (JP) | 2026-04-16 | — | — | US | claimed |
| US-12521387-B2 | Prophylactic or therapeutic drug for neurodegenerative diseases | MEDILABO RFP, INC. (JP) | 2026-01-13 | — | — | US | claimed |
| EP-4616878-A1 | CANNULA FOR RECTAL ADMINISTRATION OF AN ENEMA AND COMPOSITIONS FOR USE THEREWITH | Cosmo Technologies Ltd. (IE) | 2025-09-17 | — | — | EP | claimed |
| EP-4574173-A1 | LIQUID DELIVERY COMPOSITION | Cosmo Technologies Ltd (IE) | 2025-06-25 | — | — | EP | claimed |
| CN-116283925-B | Iminophenazine derivative coupling molecule for treating bacterial infection and application thereof | 丹诺医药(苏州）有限公司 | 2025-05-20 | — | — | CN | claimed |
| US-20250120943-A1 | RIFAMYCIN OPHTHALMIC COMPOSITION AND USE THEREOF | AMD THERAPEUTICS LLC (US) | 2025-04-17 | — | — | US | claimed |
| EP-4531844-A1 | RIFAMYCIN OPHTHALMIC COMPOSITION AND USE THEREOF | AMD Therapeutics LLC (US) | 2025-04-09 | — | — | EP | claimed |
| CN-112689758-B | Device and method for checking the effect of a drug on microorganisms | 上海宜晟生物科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| WO-2025064599-A1 | RIFAMYCIN COMPOSITION FOR TREATING SARCOPENIA | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2025-03-27 | — | — | WO | claimed |
| CN-119300821-A | Ophthalmic compositions of rifamycin and uses thereof | AMD治疗有限责任公司 | 2025-01-10 | — | — | CN | claimed |
| US-4431735-A | FERMENTATION OF HUMICOLA OR MONOCILLIUM | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1984-02-14 | — | — | US | claimed |
| US-4409209-A | POTENTIATION OF ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1983-10-11 | — | — | US | claimed |
| US-4353826-A | ANTITUBERCULAR ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1982-10-12 | — | — | US | claimed |
| US-4341785-A | Imidazo-rifamycin derivatives with antibacterial utility | ALFA FARMACEUTICI S.P.A. (IT) | 1982-07-27 | — | — | US | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
| US-4312866-A | FOR INTRA-ARTICULAR INJECTION | DR. L. ZAMBELETTI S.P.A. (IT) | 1982-01-26 | — | — | US | claimed |
| US-4261891-A | BACTERICIDES, ANTITUBERCULAR AGENTS | CIBA-GEIGY CORPORATION (US) | 1981-04-14 | — | — | US | claimed |
| US-4193920-A | BACTERICIDES | DSO "PHARMACHIM" (BG) | 1980-03-18 | — | — | US | claimed |
| US-3979376-A | ANTIBIOTICS | GRUPPO LEPETIT S.P.A. (IT) | 1976-09-07 | — | — | US | claimed |
| US-3963705-A | Process for the preparation of 3-iminomethyl derivatives of rifamycin SV | ARCHIFAR INDUSTRIE CHIMICHE DEL TRENTINO S.P.A. (IT) | 1976-06-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102392-A1 | PROPHYLACTIC OR THERAPEUTIC DRUG FOR NEURODEGENERATIVE DISEASES | MAPT, SNCA, FUS | ABCB11 488/4885TBXA2R 4680/4885CHRM1 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.